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Abstract
Several studies have confirmed that the breast tumor microenvironment drives cancer pro-
gression and metastatic development. The aim of our research was to investigate the prog-
nostic significance of the breast tumor microenvironment in untreated early breast cancer
patients. Therefore, we analyzed the association of the expression of α-SMA, FSP, CD105
and CD146 in CD34-negative spindle-shaped stromal cells, not associated with the vascu-
lature, in primary breast tumors with classical prognostic marker levels, metastatic recur-
rence, local relapse, disease-free survival, metastasis-free survival and the overall survival
of patients. In the same way, we evaluated the association of the amount of intra-tumor stro-
ma, fibroblasts, collagen deposition, lymphocytic infiltration and myxoid changes in these
samples with the clinical-pathological data previously described. This study is the first to
demonstrate the high CD105 expression in this stromal cell type as a possible independent
marker of unfavorable prognosis in early breast cancer patients. Our study suggests that
this new finding can be useful prognostic marker in the clinical-pathological routine.
Introduction
Breast cancer (BC) is one of the most common cancers among women worldwide. Statistics in-
dicate that the BC mortality rate in 2000 was 26.7 and 24.2 in Argentina and the United States,
respectively; these specific rates are expressed as the number of deaths per year and per 100,000
inhabitants [1], Bulletin N° 96 of Malignant tumor mortality, 1993–1996 and 1997–2000
PLOSONE | DOI:10.1371/journal.pone.0121421 March 24, 2015 1 / 17
OPEN ACCESS
Citation: Martinez LM, Labovsky V, de Luján
Calcagno M, Davies KM, Rivello HG, Bianchi MS,
et al. (2015) CD105 Expression on CD34-Negative
Spindle-Shaped Stromal Cells of Primary Tumor Is
an Unfavorable Prognostic Marker in Early Breast
Cancer Patients. PLoS ONE 10(3): e0121421.
doi:10.1371/journal.pone.0121421
Academic Editor: Rosa Serra, University of
Alabama at Birmingham, UNITED STATES
Received: June 26, 2014
Accepted: February 12, 2015
Published: March 24, 2015
Copyright: © 2015 Martinez et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: Grant PICT2006 from the National Agency
for Science and Technology, Argentina (NAC; http://
www.agencia.mincyt.gob.ar/). Grant PIP2011 from
the National Council of Scientific and Technical
Research (CONICET), Argentina (NAC; http://www.
conicet.gov.ar/). Grant 2006–2008, 2009–2011 and
2011–2013 from the Roemmers Foundation,
Argentina (NAC; http://www.roemmers.com.ar/). The
funders had no role in study design, data collection
(2002). National Programme of Health Statistics. Department of Statistics and Health Informa-
tion, Ministry of Health, Argentina]. Moreover, a study conducted in Argentina between 2008
and 2010 indicated that the highest mortality by cancer in women corresponded to BC, with an
annual average of cases of 5,367 per 25,618 (21%) [Bureau of National Statistics and Health In-
formation (2013). Department of Statistics and Health Information, Ministry of Health,
Argentina].
In the past decades, many researchers have focused primarily on tumor cells. However, ac-
cumulated evidence indicates that tumors are composed of tumor parenchyma and stroma—
two discrete but interactive parts that cross-talk to promote tumor growth. Recently, many
studies have demonstrated that the breast tumor microenvironment plays an important role in
tumor initiation and disease progression [2, 3]. The tumor microenvironment or stroma is
formed by cellular and extracellular components [4]. The cellular component includes different
types of cells, including myofibroblasts, fibroblasts, myoepithelial cells, blood and lymphatic
endothelial cells and their precursors, pericytes, inflammatory cells and mesenchymal stem
cells (MSCs) [5]. It is widely recognized that these auxiliary cells collaborate with BC cells to
create a tumor-permissive microenvironment capable of providing continuous support for
tumor growth, invasion and metastasis [4].
In breast carcinomas, most stromal cells are fibroblasts, and approximately 80% of them are
myofibroblasts [3, 6]. These latter cells maintain a spindle shape and have an activated pheno-
type characterized by increased expression of α-smooth muscle actin (α-SMA) and fibroblast
surface protein (FSP), among others markers, and are referred to as cancer-associated fibro-
blasts (CAFs) [7, 8]. In light of recent findings, CAFs are believed to have 4 major distinct ori-
gins: (1) resident mammary fibroblasts [9]; (2) cancer cells that undergo epithelial
mesenchymal transition [10]; (3) endothelial cells by endothelial mesenchymal transition [11]
and (4) bone marrow MSCs as well as breast tissue-resident MSCs [10, 12]. Independent of the
source, CAFs are spindle-shaped stromal cells with negative CD34 expression in invasive breast
carcinoma [13, 14]. Other typical markers of MSCs such as CD105 and CD146 could be pres-
ent in this stromal cell type. Until now, the expression of CD105 and CD146 was described in
endothelial progenitors [15–18] and pericytes [19, 20]. Moreover, it was reported that the
immunoexpression of microvessels containing CD105 or CD146-labeled endothelial cells is a
marker of poor outcome in BC [15–18]. However, the prognostic importance of the expression
of α-SMA, FSP, CD105 and CD146 in CD34-negative spindle-shaped stromal cells, not associ-
ated with the vasculature, from primary breast tumors remains unknown.
Regarding the above observations, the purpose of our research was to study the prognostic
relevance of the tumor microenvironment in a population of BC patients (BCPs) with early-
stage disease. Specifically, we analyzed the association of the expression of α-SMA, FSP, CD105
and CD146 in CD34-negative spindle-shaped stromal cells, not associated with the vasculature,
in primary breast tumors with classical prognostic marker levels, metastatic recurrence, local
relapse, disease-free survival, metastasis-free survival and the overall survival of patients. In the
same way, we evaluated the association of the amount of intra-tumor stroma, fibroblasts, colla-
gen deposition, lymphocytic infiltration and myxoid changes in these samples with the clini-
cal-pathological data previously described. In this manuscript, our stromal parameters are
called non-classical prognostic markers.
Materials and Methods
This study retrospectively enrolled unselected consecutive cases with a confirmed histological
diagnosis made by specialist breast pathologists. In particular, malignant breast tissues ob-
tained by surgical resection from 56 BCPs, as well as non-malignant breast tissue biopsies from
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10 control women, were collected. The age of patients ranged between 42 and 80 years, while
that for the control women ranged between 45 and 75 years. Key inclusion criteria for BCPs
were women with breast infiltrative ductal carcinoma, I and II clinical stages (according to the
International Union Against Cancer TNM classification system) and a minimum period of 10
years from the surgery, as well as control women who had negative results of BC. Exclusion cri-
teria were neoadjuvant therapy for BCPs, as well as tissue not available for both groups.
The non-malignant breast tissues used as control were classified as normal breast tissue
(n = 6), mammary dysplasia (fibrocystic breast disease, n = 3) and sclerosed fibroadenoma
(n = 1).
Paraffin blocks from breast tissues fixed in 10% neutral buffered formalin were retrieved
from the surgical archives of the Pathology Department of Italian Hospital, Ciudad de Buenos
Aires, Argentina, and then were sectioned at 4-μm thickness for all of the assays. This study
and informed consent were approved by the IBYME and Italian Hospital Ethical Committees,
and the work was performed in accordance with the principles of the Helsinki Declaration.
The informed consent form was signed by each patient or their relatives. The data were anony-
mous and coded.
After surgery, all of BCPs were treated by specialized Oncologists of Italian Hospital using
the indicated hormonal- and/or radio- and/or chemo-therapy depending on their clinical and
tumor histopathological characteristics in according to the recommendations of the European
Society for Medical Oncology [21].
The cases were collected into a common database. A complete patient record contained in-
formation concerning the following clinicopathological characteristics: age, tumor size, histo-
logical grade, status of HER2/neu, hormonal receptors [estrogen receptors (ER) and
progesterone receptors (PR)] and regional lymph nodes (classical prognostic markers), meta-
static recurrence, local relapse, disease-free survival, metastasis-free survival and
overall survival.
Analysis of the classical prognostic markers were a priority determined according to Italian
Hospital´s protocols as described Wernicke M et al. [22]. Specifically: a) we subdivided our
population into two age groups:< 50 and 50 years old; b) the tumor size was subdivided
into< 2 and 2 cm; c) histological grade was evaluated based on the Scarff-Bloom-Richard-
son grading system [23] and was categorized as well differentiated/intermediate (G1/G2) and
poor (G3); d) hormonal receptor and HER2/neu expression was considered to be negative or
positive according to Wernicke M et al. [22]; and e) the presence of regional metastatic lymph
nodes was recorded as negative (negative nodes in axillary dissection or negative sentinel
lymph node when this technique was performed) or positive (including micrometastasis)
(Table 1).
Immunohistochemical assay
Sections were deparaffinized and hydrated to passages in xylene and 100, 96 and 70% ethanol
and then were incubated in citrate buffer (0.01 M, pH 6) at 60°C for 25 min. Endogenous per-
oxidase was blocked by incubating the tissues with 3% hydrogen peroxide for 5 min. Next, pro-
teins were blocked using 1% bovine serum albumin in phosphate-buffered saline-0.1% Tween-
20 for 1 h. Thereafter, the tissues were incubated with the following primary human antibodies
(Abs): anti- α-SMA (mouse IgG2a; MAB1420; R&D Systems), FSP (mouse IgM; F4771; Sigma-
Aldrich), CD105 (goat IgG; AF1097; R&D Systems) or CD146 (goat IgG; AF932; R&D Sys-
tems) overnight at 4°C in a humid environment. Next, LSAB+ System-HRP (K0690; Dako)
and 3-3´-diaminobenzidine (Liquid DAB+ Substrate Chromogen System; K3468; Dako) were
used according to the manufacturer’s specifications. Hematoxylin (Biopur) was used for
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counterstaining, followed by mounting with Canada Balsam (Canadax, Biopur). Tissue sec-
tions were also incubated without primary Abs and with irrelevant mouse IgG2a (X0943;
Table 1. Clinicopathological characteristics of 56 untreated early breast cancer patients.
Characteristics Patients (n) Patients (%)
Age (years)
< 50 8 14.28
 50 43 76.79
Unknown 5 8.93
Tumor size (cm)
<2 41 73.21
 2 14 25.00
Unknown 1 1.79
Histological grade
G1/G2 32 57.14
G3 23 41.07
Unknown 1 1.79
HER2/neu status
Negative 32 57.14
Positive 23 41.07
Unknown 1 1.79
ER status
Negative 15 26.79
Positive 40 71.43
Unknown 1 1.79
PR status
Negative 14 25.00
Positive 41 73.21
Unknown 1 1.79
Regional lymph nodes
Negative 40 71.43
Positive 14 25.00
Unknown 2 3.57
Metastatic recurrence
Negative 39 69.64
Positive 11 19.64
Unknown 6 10.71
Sites of metastasis
No metastasis 39 69.64
Bone 5 8.93
Viscera and non-regional lymph nodes 3 5.36
Bone + viscera and non-regional lymph nodes 3 5.36
Unknown 6 10.71
Local relapse
Negative 45 80.36
Positive 5 8.93
Unknown 6 10.71
HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor
doi:10.1371/journal.pone.0121421.t001
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Dako), irrelevant mouse IgM (X0942; Dako) or total normal goat IgG (AB-108-C; R&D Sys-
tems) as negative controls in all of the runs. Each sample was assayed in duplicate.
The immunohistochemical reactions were estimated independently by two pathologists.
The agreement in immunohistochemical evaluation between the two observers was 85.58%
(Kappa value: 0.8175). In cases with no agreement, a re-evaluation was performed using a dou-
ble-headed microscope, and staining was discussed until a consensus was achieved. Each slide
was initially examined by these pathologists at 100× magnification for an overall view, and
then 5 representative fields at 400× magnification were systematically evaluated. The immuno-
histochemical signal was scored based on the method by Surowiak P et al. [24]. Briefly, a quan-
titative score was assigned representing the percentage of stromal cells with positive staining
[0% (score 0);<10% (score 1); 10–50% (score 2); 51–80% (score 3) or>80% (score 4)]. The in-
tensity of staining in positive cells was assigned an intensity score [absent (score 0); low (score
1); moderate (score 2) or intense (score 3) by comparison with internal controls]. The quantita-
tive score and intensity score were added to obtain a total score that ranged from 0 to 7. The in-
tensity score was based on the relative intensities of stromal cell staining in reference to the
staining present in specific cells of breast tissue. As previously described, breast tissue demon-
strated the immunoreactivity of α-SMA on smooth muscle cells and myoepithelial cells [25],
FSP on tissue macrophages [26] and CD105 and CD146 on endothelial cells [15–18]. These in-
ternal references were used as internal positive controls.
Although it is known that the spindle-shaped stromal cells have negative CD34 expression
in invasive breast carcinoma [13, 14], we analyzed its expression in the evaluated stromal cells
to confirm that we did not consider individual endothelial progenitor cells in malignant tissues.
Specimens were incubated with Ab anti-CD34 (mouse IgG1; M7165; Dako) or irrelevant
mouse IgG1 (MAB002; R&D Systems) as a negative isotype control in all of the runs. Each
sample was also assayed in duplicate. Moreover, we also performed two-color immunohis-
tochemistry for CD105 and CD34. The double immunostaining involved sequential staining of
each primary Ab anti-CD105 (detected by LSAB+ System-HRP and 3-3´-diaminobenzidine as
previously described) and CD34 [detected by Biotinylated anti-mouse IgG (H+L; BA-2000;
Vector Laboratories), Vectastain ABC-Alkaline Phosphatase kit (Ak-5000; Vector Laborato-
ries) and Vector Red Substrate Kit (SK-5100; Vector Laboratories) according to the manufac-
turer’s specifications]. Nuclei were counterstained with hematoxylin followed by mounting
with VectaMount mounting medium (H-5000; Vector Laboratories). Tissue sections were also
sequentially incubated with total normal goat IgG and irrelevant mouse IgG1 as the negative
control in all of the runs. Each sample was also assayed in duplicate. In parallel, we also per-
formed single immunostaining for CD34 using red chromogen in these tissue sections as previ-
ously described. Tissue sections were also incubated with irrelevant mouse IgG1 as a negative
isotype control in all of the runs. Each sample was also assayed in duplicate.
Hematoxylin and Eosin (H&E) staining
The study of tumor stromal histological features as intra-tumor stroma and amount of fibro-
blasts, collagen deposition, lymphocytic infiltration and myxoid changes were determined by
routine H&E staining. First, using a 5× objective, the most invasive tumor area of the whole tis-
sue slide was selected. Subsequently, using a 10× objective, only fields were evaluated where
both stroma and tumor were present as described Kruijf EM et al. [27]. Specifically, the stromal
myxoid changes were evaluated based onWernicke M et al. [28]. The slides were estimated in-
dependently by two pathologists as previously described. The amount of fibroblasts, collagen
deposition, lymphocytic infiltration and myxoid changes was scored as absent (score 0); scanty
(score 1); moderate (score 2) or large amount (score 3) by these pathologists. The agreement in
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the evaluation of these stromal features between the two observers was 89.42% (Kappa value:
0.8455). By contrast, the intra-tumor stroma amount was expressed as a percentage. In this
case, the intraclass correlation coefficient (ICC) to estimated the observer variation was 0.8967.
Each sample was assayed in duplicate.
Statistical analysis
The difference in stromal marker expression between breast malignant tissues and non-malig-
nant tissues was analyzed by the Mann-Whitney test.
To evaluate the associations between non-classical prognostic markers and clinicopatholog-
ical characteristics in BCPs, we identified a cut-off value according to the results of previous
studies [29, 30]. Thus, the cut-off value ( or>) was used for binomial classification of tumor
samples: negative/low or high expression, as well as negative or positive expression as appropri-
ate (stromal cell markers), absent/scanty or large amount (fibroblasts, collagen deposition, lym-
phocytic infiltration and myxoid changes) and or> percentage (intra-tumor stroma). To
identify the optimal cut-off value, Q1, median and Q3 values were tested individually in uni-
variate analysis with respect to overall survival of the BCPs. The cut-off value that showed the
lowest p-value was chosen. The optimal cut-off values of the expression of α-SMA, FSP,
CD105 and CD146, as well as those for the amount of intra-tumor stroma, fibroblasts, collagen
deposition, lymphocytic infiltration and myxoid changes were as follows: 5 (Q1), 0 (Q1), 3
(Q3), 0 (median or Q1), 50% (median), 1 (median or Q1), 1 (Q1), 1 (Q1, median, Q3) and 1
(Q1, median, Q3), respectively. Consequently, the association of non-classical prognostic
markers with classical prognostic markers, metastatic recurrence and local relapse was ana-
lyzed using Fisher’s exact test.
Disease-free survival and metastasis-free survival were calculated as the period from the
date of surgery to the first observation of tumor recurrence (metastatic recurrence and/or local
relapse) and metastatic recurrence, respectively, or last follow-up. The overall survival was cal-
culated as the period from the date of surgery until death from the BC cause or last follow-up.
Univariate analysis of disease-free survival, metastasis-free survival and overall survival was es-
timated according to the Kaplan-Meier method and analyzed by the log-rank (Mantel-Cox)
test. Once significant variables (classical and non-classical prognostic markers) were identified,
we applied the Cox proportional hazards model to the multivariate survival analysis incorpo-
rating only these significant variables.
Multiple testing was corrected using Benjamini-Hochberg false discovery rate [31].
A p-value<0.05 was considered to be statistically significant (two sided p-value). Statistical
analysis was performed by an expert statistician using SPSS software (version 18.00, Chicago,
Illinois) and InfoStat (version 2012, InfoStat Group, National University of Cordoba,
Argentina).
Results
Expression of α-SMA, FSP, CD105 and CD146 in spindle-shaped
stromal cells, not associated with the vasculature, in malignant and non-
malignant breast tissues
BC tissues (n = 54) exhibited significantly higher stromal cell expression of α-SMA than non-
malignant breast tissues (n = 9) [data expressed as median (interquartile range), Mann-Whit-
ney test]: 6 (5–7) vs. 4 (0–4), respectively (p = 0.0001; Benjamini-Hochberg adjusted
p = 0.0065). In addition, stromal cells of BC tissue expressed FSP (n = 53) and CD105 (n = 52)
[data expressed as median (interquartile range)]: 2 (0–3) in both cases, but there was no
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expression of these markers in non-malignant breast tissue (n = 8 and 6, respectively). By con-
trast, data showed expression of CD146 in both types of tissues, but no significant difference
was found [n = 56 (BC samples) and n = 10 (non-malignant samples)] (Fig. 1).
Expression of CD34, as well as that of CD105 and CD34, in spindle-
shaped stromal cells, not associated with the vasculature, in malignant
breast tissues
Spindle-shaped stromal cells, not associated with vasculature, in BC tissues (n = 56) were
found to be negative for CD34 expression (Fig. 2). In parallel, the double immunohistochemis-
try assay showed that the positive CD105-stromal cells with a spindle shape, not associated
with vasculature, in BC tissues (n = 52) were negative for CD34 (Fig. 3). These findings demon-
strate that these cells are not individual endothelial progenitor cells.
Association between non-classical prognostic markers and classical
prognostic markers, metastatic recurrence and local relapse of BCPs
CD105 expression in stromal cells with a spindle shape, not associated with the vasculature,
was found to be significantly associated with tumor size in our patients (p = 0.0210). Thus,
46.15% (6/13) of the patients with tumors greater than 2 cm showed high CD105 expression,
Fig 1. Expression of α-SMA, FSP, CD105 and CD146 in malignant and non-malignant breast tissues. A
Representative immunohistochemistry staining for α-SMA, FSP, CD105 and CD146 in stromal cells of
primary tumor tissues from breast cancer (BC) patients and non-malignant breast tissues. Reactions were
evaluated in spindle-shaped stromal cells, not associated with the vasculature. The arrows show positive
staining of evaluated stromal cells (S) and smooth muscle cells (S M), myoepithelial cells (MY), tissue-
associated macrophages (M) and endothelial cells (E) used as internal positive controls as previously
described. B No staining was observed in both types of tissues when we incubated them without primary
antibodies and with irrelevant mouse IgG2a (for α-SMA), irrelevant mouse IgM (for FSP) or total normal goat
IgG (for CD105 and CD146) as negative controls. Nuclei were counterstained with hematoxylin (purple).
Original magnification A and B: 400×. The scale bars represent 50 μm.
doi:10.1371/journal.pone.0121421.g001
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whereas 13.16% (5/38) of patients with tumors smaller than 2 cm showed high CD105 expres-
sion (Table 2). However, after the adjustment for multiple tests, this finding was considered
not significant (Benjamini-Hochberg adjusted p = 0.2292). Moreover, high CD105 expression
was associated with a significantly higher risk of developing metastasis (p = 0.0012; Benjamini-
Hochberg adjusted p = 0.0224). Thereby, 63.64% (7/11) of samples from patients with metasta-
sis had high CD105 expression, whereas 11.11% (4/36) of cases that remained metastasis-free
Fig 2. Expression of CD34 in tumor stromal cells. Representative negative staining for CD34 in the
evaluated spindle-shaped stromal cells, not associated with the vasculature, of primary tumor tissue from a
breast cancer patient. The arrow shows an example of CD34-positive staining only in the endothelial cells
(E). No staining was observed in the tissues when we incubated them with irrelevant mouse IgG1 as a
negative isotype control. Nuclei were counterstained with hematoxylin (purple). Original magnification: 400×.
The scale bar represents 50 μm.
doi:10.1371/journal.pone.0121421.g002
Fig 3. Expression of CD105 and CD34 in tumor stromal cells. i Single immunohistochemistry for CD34
(detected by red chromogen) shows a representative example of CD34-positive staining in the endothelial
cells (E). ii Double immunohistochemistry for CD105 and CD34 (detected by brown and red chromogen,
respectively) shows a representative example of co-staining of CD105 and CD34 in the endothelial cells (E)
and CD105-positive staining only in evaluated stromal cells (S) of primary tumor tissue from a breast cancer
patient. No staining was observed in the tissues when we incubated them with irrelevant mouse IgG1 (for
CD34) or sequentially incubated with total normal goat IgG and irrelevant mouse IgG1 (for CD105/ CD34) as
negative isotype controls (iii and iv; respectively). Nuclei were counterstained with hematoxylin (purple).
Original magnification: 400×. The scale bars represent 50 μm.
doi:10.1371/journal.pone.0121421.g003
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had high CD105 expression (Table 2). Furthermore, when we considered the sites of metastases,
we observed that 80.00% (4/5) of samples from patients with bone metastasis had high CD105
expression as well as 100.00% (3/3) of samples from patients with bone and visceral/non
Table 2. Association of stromal cell expression of α-SMA, FSP, CD105 and CD146 with classical prognostic markers, metastatic recurrence and
local relapse of 56 untreated early breast cancer patients.
Characteristics α-SMA FSP CD105 CD146
n High
expression
p (adjusted
p)*
n Positive p (adjusted
p)*
n High
expression
p (adjusted
p)*
n Positive p (adjusted
p)*
Age (years)
< 50 8 5 (62.50) >0.9999 8 3 (37.50) 0.7032 8 2 (25.00) >0.9999 8 2 (25.00) 0.4448
 50 41 26 (63.41) (>0.9999) 40 20
(50.00)
(0.9497) 39 9 (23.08) (>0.9999) 43 19
(44.19)
(0.9249)
Tumor size (cm)
<2 39 28 (71.79) 0.1913 38 22
(57.89)
0.2147 38 5 (13.16) 0.0210 41 16
(39.02)
>0.9999
 2 14 7 (50.00) (0.8084) 14 5 (35.71) (0.8036) 13 6 (46.15) (0.2292) 14 6 (42.86) (>0.9999)
Histological grade
G1/G2 30 21 (70.00) 0.5648 29 16
(55.17)
0.7804 30 5 (16.67) 0.3270 32 11
(34.37)
0.4055
G3 23 14 (60.87) (0.9134) 23 11
(47.83)
(0.9736) 21 6 (28.57) (0.8399) 23 11
(47.83)
(0.9319)
HER2/neu status
Negative 32 20 (62.50) 0.5647 31 15
(48.39)
0.5822 28 6 (21.43) >0.9999 32 12
(37.50)
0.7818
Positive 21 15 (71.43) (0.9247) 21 12
(57.14)
(0.8868) 23 5 (21.74) (>0.9999) 23 10
(43.48)
(0.9571)
ER status
Negative 15 10 (66.67) >0.9999 15 7 (46.67) 0.7619 13 3 (23.08) >0.9999 15 8 (53.33) 0.2396
Positive 38 25 (65.79) (>0.9999) 37 20
(54.05)
(0.9597) 38 8 (21.05) (>0.9999) 40 14
(35.00)
(0.8483)
PR status
Negative 14 8 (57.14) 0.5147 14 6 (42.86) 0.5364 12 2 (16.67) 0.7158 14 8 (57.14) 0.2059
Positive 39 27 (69.23) (0.9496) 38 21
(55.26)
(0.9009) 39 9 (23.08) (0.9472) 41 14
(34.15)
(0.8174)
Regional lymph nodes
Negative 38 28 (73.68) 0.0524 37 22
(59.46)
0.2086 36 5 (13.89) 0.1180 40 15
(37.50)
0.7582
Positive 14 6 (42.86) (0.4038) 14 5 (35.71) (0.8037) 14 5 (35.71) (0.6721) 14 6 (42.86) (0.9643)
Metastatic recurrence
Negative 37 25 (67.57) 0.4856 37 19
(51.35)
0.6180 36 4 (11.11) 0.0012 39 14
(35.90)
0.3109
Positive 11 6 (54.55) (0.9495) 11 4 (36.36) (0.9096) 11 7 (63.64) (0.0224) 11 6 (54.55) (0.8485)
Local relapse
Negative 43 28 (65.12) >0.9999 44 21
(47.73)
>0.9999 42 9 (21.43) 0.5776 45 18
(40.00)
>0.9999
Positive 5 3 (60.00) (>0.9999) 4 2 (50.00) (>0.9999) 5 2 (40.00) (0.8902) 5 2 (40.00) (>0.9999)
HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor; α-SMA: α-smooth muscle actin; FSP: Fibroblast
surface protein, CD105: Endoglin; CD146: Melanoma cell adhesion molecule.
*The association between variables was performed using the Fisher Exact-test. Multiple testing adjusted p-values were computed using the Benjamini-
Hochberg correction
doi:10.1371/journal.pone.0121421.t002
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regional lymph node involvement. By contrast, no sample was obtained from patients with
only visceral/non regional lymph node metastasis with high expression of this marker.
In addition, we found that the quantity of intra-tumor stroma was significantly associated
with size and histological grade of the tumors in our patients (p = 0.0045 and 0.0120, respec-
tively). So, 67.57% (25/37) of patients with tumors smaller than 2 cm were stroma-high
(>50%), whereas 21.43% (3/14) patients with tumors greater than 2 cm were stroma-high. Ad-
ditionally, 71.43% (20/28) of samples with G1/G2 were stroma-high, whereas 34.78% (8/23) of
samples with poorly differentiated tumors (G3) were stroma-high (Table 3 and Fig. 4). Howev-
er, after the Benjamini-Hochberg correction, these finding were considered not significant
(Benjamini-Hochberg adjusted p = 0.0737 and 0.1747, respectively).
Regarding myxoid changes, we observed that they were significantly associated with size
and histological grade of tumors in our patients (p = 0.0450 and 0.0011, respectively). As a re-
sult, 100.00% (14/14) of patients with tumors greater than 2 cm had a large amount of myxoid
changes, whereas 72.97% (27/37) of patients with tumors smaller than 2 cm had a large amount
of myxoid changes. Additionally, 100% (23/23) of samples with poorly differentiated tumors
had a large amount of myxoid changes, whereas 64.28% (18/28) of samples with G1/G2 had a
Table 3. Association of stromal histological features with classical prognostic markers, metastatic recurrence and local relapse of 56 untreated
early breast cancer patients.
Characteristics n Intra-tumor stroma Fibroblasts Collagen deposition Lymphocytic inﬁltration Myxoid changes
> 50 p (adjusted p)* Large amount p (adjusted p)* Large amount p (adjusted p)* Large amount p (adjusted p)* Large amount p (adjusted p)*
Age (years)
< 50 8 4 (50.00) >0.9999 4 (50.00) >0.9999 4 (50.00) 0.1868 1 (12.50) 0.6887 8 (100.00) 0.1767
 50 40 22 (55.00) (>0.9999) 18 (45.00) (>0.9999) 31 (77.50) (0.8739) 8 (20.00) (0.9598) 30 (75.00) (0.8573)
Tumor size (cm)
<2 37 25 (67.57) 0.0045 20 (54.05) 0.3487 28 (75.68) >0.9999 4 (10.81) 0.0519 27 (72.97) 0.0450
 2 14 3 (21.43) (0.0737) 5 (35.71) (0.8381) 10 (71.43) (>0.9999) 5 (35.71) (0.4533) 14 (100.00) (0.4211)
Histological grade
G1/G2 28 20 (71.43) 0.0120 13 (46.43) 0.7812 21 (75.00) >0.9999 3 (10.71) 0.2682 18 (64.28) 0.0011
G3 23 8 (34.78) (0.1747) 12 (52.17) (0.9654) 17 (73.91) (>0.9999) 6 (26.09) (0.8569) 23 (100.00) (0.0240)
HER2/neu status
Negative 30 17 (56.67) 0.7828 16 (53.33) 0.5725 21 (70.00) 0.5180 4 (13.33) 0.4601 22 (73.33) 0.1666
Positive 21 11 (52.38) (0.9495) 9 (42.86) (0.8928) 17 (80.95) (0.9425) 5 (23.81) (0.9273) 19 (90.48) (0.9093)
ER status
Negative 14 9 (64.29) 0.5327 5 (35.71) 0.3487 9 (64.29) 0.4723 4 (28.57) 0.2362 11 (78.57) >0.9999
Positive 37 19 (51.35) (0.9182) 20 (54.05) (0.8381) 29 (78.38) (0.9374) 5 (13.51) (0.8595) 30 (81.08) (>0.9999)
PR status
Negative 13 7 (53.85) >0.9999 5 (38.46) 0.5230 8 (61.54) 0.2743 3 (23.08) 0.6764 10 (76.92) >0.9999
Positive 38 21 (55.26) (>0.9999) 20 (52.63) (0.9135) 30 (78.95) (0.8356) 6 (15.79) (0.9528) 31 (81.58) (>0.9999)
Regional lymph nodes
Negative 37 22 (59.46) 0.5204 18 (48.65) >0.9999 28 (75.68) 0.7193 7 (18.92) >0.9999 29 (78.38) 0.7134
Positive 13 6 (46.15) (0.9337) 6 (46.15) (>0.9999) 9 (69.23) (0.9423) 2 (15.38) (>0.9999) 11 (84.62) (0.9536)
Metastatic recurrence
Negative 36 19 (52.78) 0.7310 20 (55.56) 0.3177 25 (69.44) 0.2440 6 (16.67) 0.6631 28 (77.78) >0.9999
Positive 11 7 (63.64) (0.9481) 4 (36.36) (0.8324) 10 (90.91) (0.8196) 3 (27.27) (0.9442) 9 (81.82) (>0.9999)
Local relapse
Negative 42 22 (52.38) 0.3623 23 (54.76) 0.1882 31 (73.81) >0.9999 7 (16.67) 0.2397 34 (80.95) 0.5694
Positive 5 4 (80.00) (0.8475) 1 (20.00) (0.8501) 4 (80.00) (>0.9999) 2 (40.00) (0.8263) 3 (60.00) (0.8987)
HER2: Human epidermal growth factor receptor 2; ER: Estrogen receptor; PR: Progesterone receptor.
*The association between variables was performed using the Fisher Exact-test. Multiple testing adjusted p-values were computed using the Benjamini-
Hochberg correction
doi:10.1371/journal.pone.0121421.t003
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large amount of myxoid changes (Table 3 and Fig. 4). After the adjustment for multiple tests,
only the association between myxoid changes and tumor histological grade remains significant
(Benjamini-Hochberg adjusted p = 0.0240).
Finally, we found no other significant association between non-classical prognostic markers
and classical prognostic markers, metastatic recurrence and local relapse in our BCPs (Tables 2
and 3).
Association between non-classical prognostic markers and disease-free
survival, metastasis-free survival and overall survival of BCPs
Kaplan-Meier curve analysis indicated that CD105 expression was significantly associated with
disease-free survival, metastasis-free survival and overall survival of our BCPs. Thus, patients
with high CD105 expression showed a shorter disease-free survival, metastasis-free survival
and overall survival than patients with negative/low CD105 expression (p = 0.0010; Benjamini-
Hochberg adjusted p = 0.0327; in all of these cases) (Table 4 and Fig. 5).
In addition, univariate survival analysis showed a significant correlation of FSP expression
with overall survival. Therefore, patients with positive FSP expression showed a greater overall
survival than patients with negative FSP expression [data expressed in months as the mean±
standard error; log-rank (Mantel-Cox) test]: 148.86±3.64 vs. 114.10±13.36, respectively;
p = 0.0400 (Fig. 5). Additionally, we observed that the quantity of lymphocytic infiltration was
Fig 4. Histological features of primary breast tumor stroma as determined by hematoxylin and eosin staining. This picture is an example of samples
with a large amount and absent/scanty amount of stroma, fibroblasts, collagen deposition, lymphocytic infiltration and myxoid changes. The arrows show
tumor fibroblasts (F), collagen deposition (C), lymphocytic infiltration (L) and myxoid changes (M C). Original magnification: 100×. The scale bars represent
200 μm.
doi:10.1371/journal.pone.0121421.g004
Table 4. Comparing of the disease-free survival, metastasis-free survival and overall survival be-
tween untreated early breast cancer patients that presented high expression and those with negative/
low expression of CD105.
Clinical data High expression* Negative/low expression*
Disease-free survival 70.64±15.40 (a) 132.01±7.62 (a)
Metastasis-free survival 81.73±15.45 (b) 136.11±6.66 (b)
Overall survival 96.62±15.51 (c) 143.58±4.42 (c)
* The data are expressed in months as mean±standard error. The p-value of a, b and c is 0.0010 [Kaplan-
Meier method and analyzed by log-rank (Mantel-Cox)-test]. The adjusted p-value of a, b and c is 0.0327
(Benjamini-Hochberg correction)
doi:10.1371/journal.pone.0121421.t004
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significantly associated with the overall survival. So, patients with a large amount of lympho-
cytic infiltration showed a shorter overall survival than those with an absent or a scanty
amount of lymphocytic infiltration [data expressed in months as mean±standard error; log-
rank (Mantel-Cox) test]: 90.22±19.50 vs. 142.86±5.48, respectively, p = 0.0160 (Fig. 5). After
Fig 5. Correlation of CD105 and FSP expression, as well as lymphocytic infiltration quantity with disease-free survival, metastasis-free survival
and overall survival of 56 untreated early breast cancer patients. A Kaplan-Meier curves show that high stromal cell expression of CD105 is associated
with a shorter disease-free survival, metastasis-free survival and overall survival of our breast cancer patients. The difference is statistically significant
[p = 0.0010 in all of cases by log-rank (Mantel-Cox)-test]. The adjusted p-value is 0.0327 (Benjamini-Hochberg correction) in all of cases. Moreover, positive
FSP expression is significantly associated with a greater overall survival of these patients [p = 0.0400 by log-rank (Mantel-Cox) test]. Furthermore, a large
amount of lymphocytic infiltration is significantly associated with a shorter overall survival of these patients [p = 0.0160, log-rank (Mantel-Cox) test]. After the
Benjamini-Hochberg adjustment, these last associations were considered not significant (adjusted p = 0.4031 and 0.2096, respectively). B Photographs
show a representative immunohistochemistry staining for tumor samples with high and negative/low stromal expression of CD105, as well as tumor samples
with positive and negative FSP expression. The arrows show positive staining of evaluated stromal cells (S), endothelial cells (E) and tissue associated-
macrophages (M) used as internal positive controls as previously described. Original magnification: 400×. The scale bars represent 50 μm.
doi:10.1371/journal.pone.0121421.g005
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the Benjamini-Hochberg correction, both associations were considered not significant (Benja-
mini-Hochberg adjusted p = 0.4031 and 0.2096, respectively).
Finally, no other significant association was found between non-classical prognostic mark-
ers and disease-free survival, metastasis-free survival and overall survival of patients (data not
shown).
Association between classical prognostic markers and disease-free
survival, metastasis-free survival and overall survival of BCPs
Univariate survival analysis showed that tumor size was significantly associated with metasta-
sis-free survival in our patients. Thus, patients with tumors greater than 2 cm had early meta-
static recurrence [p = 0.0200 by log-rank (Mantel-Cox) test]. However, the Benjamini-
Hochberg adjusted p value was 0.2382. Furthermore, no other significant association was
found between classical prognostic markers and disease-free survival, metastasis-free survival
and overall survival of patients (data not shown).
Multivariate analysis
Multivariate analysis incorporating the significant variables without adjustment for multiple
tests, demonstrated that CD105 expression was an independent predictive indicator for metas-
tasis-free survival and overall survival of our BCPs (p = 0.0040 and 0.0130, respectively)
(Table 5).
Discussion
Emerging evidence indicates that we need to consider carcinogenesis and tumor progression
not as cell autonomous, but rather as a disease involving complex multicellular interactions
within a newly formed tissue: the cancer tissue [32]. Although evidence suggests that the
Table 5. Multivariate analysis of metastasis-free survival and overall survival in 56 untreated early breast cancer patients.
Events Characteristics RR 95% C.I. p*
Metastasis- free survival CD105
High expression 6.44 1.79–23.08 0.0040
Negative/low expression 1 -
Tumor size (cm)
 2 3.42 0.98–11.92 0.0530
<2 1 -
Overall survival FSP
Positive expression 1 - 0.2590
Negative expression 0.36 0.06–2.13
CD105
High expression 9.56 1.61–56.75 0.0130
Negative/low expression 1 -
Lymphocytic inﬁltration
Large amount 5.19 0.94–28.60 0.0590
Absent/scanty amount 1 -
FSP: Fibroblast surface protein, CD105: Endoglin; C.I.: Conﬁdence interval; RR: Relative risk.
*The Cox Proportional Hazards Model was applied to the multivariate survival analysis
doi:10.1371/journal.pone.0121421.t005
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tumor-related stroma influences tumor behavior, no clinically applicable prognostic marker
has emerged.
First, we evaluated the relationship between the intra-tumor stroma and clinicopathological
data in our BCPs. The high quantity of the intra-tumor stroma was shown to be significantly
associated with favorable classical prognostic markers such as size< 2 cm and low histological
grade of the breast tumors. However, after the Benjamini-Hochberg correction, these finding
were considered not significant. Meanwhile, Kruijf EM et al. [27] identified the tumor-stroma
ratio as an independent prognostic factor in invasive BC and observed a shorter relapse-free
period and overall survival in patients with stroma-rich tumors than in those with stroma-poor
tumors. In contrast, Ahn et al. [33] did not find significant association between quantity of
stroma and clinicopathological data of patients. Based on conflicting reports regarding the
quantification of intra-tumor stroma, we not only examined its quantitative nature but also its
qualitative nature.
In agreement with other authors, our data showed that the stromal cell expression of α-
SMA and FSP was different between women with breast carcinoma and those with non-malig-
nant breast tissue [34, 35], suggesting that these typical markers of CAFs could be useful in pre-
dicting the behavior of a patient's tumor. In this way, although there is a significant body of
literature that demonstrates the role of FSP as a marker for BC progression [35, 36], the focus
of these studies has been its expression in cancer cells. Our results showed that positive FSP ex-
pression was significantly associated with prolonged overall survival, suggesting that FSP-ex-
pressing CAFs are related to a favorable prognosis of early BCPs. However, this finding was
not significant with adjustment for multiple tests.
We also observed that CD34-negative stromal cells with a spindle shape, not associated with
the vasculature, in BC tissue expressed CD105 but we did not observe its expression in non-
malignant breast tissue. Furthermore, we found that high CD105 expression in this stromal cell
type was significantly associated with tumor size 2 cm. However, after the Benjamini-Hoch-
berg correction, this result was considered not significant. Simultaneously, we demonstrated
that high CD105 expression was significantly associated with a higher risk of developing metas-
tasis and with a shorter disease-free survival, metastasis-free survival and overall survival of
our patients. Moreover, after the adjustment for multiple tests, these last associations remain
significant. Our results could be related to those of Li C et al. [37], who reported that the plas-
ma levels of CD105 were significantly increased in patients with early-stage BC who developed
distant metastasis compared with those in disease-free patients. In addition, if we consider the
sites of metastases, high CD105 expression may be a predictive marker for the occurrence of
skeletal metastasis in our BCPs. Indeed, the literature supports that BC relapses from bone
marrow years after remission, suggesting a preferential niche in the hematopoietic microenvi-
ronment for circulating tumor cells [38]. Although there is no doubt that stromal CD105 ex-
pression has important prognostic implications, more efforts are required to determine if this
expression is bone metastasis specific.
Concerning CD146 expression, our data indicated that malignant and non-malignant breast
tissue expressed this marker, but no significant difference was found. Because we quantified
the stromal cell expression of CD146 only in the tumor stroma that was not associated with the
vasculature, it is possible that their expression was reduced or lacking as a consequence of the
low oxygen levels in the reactive stromal compartment [39].
In reference to lymphocytic infiltration, our results only without Benjamini-Hochberg ad-
justment indicated that the high quantity of this infiltration was significantly associated with a
shorter overall survival of our BCPs, supporting the belief that lymphocytic infiltration could
be associated with poor prognosis as reported in previous studies [40–42]. By contrast, Mo-
hammed ZM and et al. [43] reported that tumor lymphocytic infiltration was independently
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associated with improved overall survival of BCPs. Further study to characterize the type of
lymphocytes present in the tumor stroma of our patients should be conducted in the future.
Another stromal signature are the myxoid changes, which consist of stromal reactions com-
posed of amphophilic or slightly basophilic vacuolated material and are found among the colla-
gen fibers. Tissues rich in hyaluronan lead to myxoid changes. Thus, strong evidence suggests
that hyaluronan is associated with the invasive potential and poor outcome in BCPs [44, 45].
In accordance with previous results of other authors [28], we found that a large amount of stro-
mal changes was associated with a high histological grade. We also observed that a large
amount of myxoid changes was significantly associated with tumor size 2 cm in our patients.
However, after the adjustment for multiple tests, only the first association previously described
remains significant. Therefore, the presence of myxoid changes could help identify aggressive-
tumors in early stage-BCPs.
In conclusion, this is the first demonstration of high CD105 expression in CD34-negative
spindle-shaped stromal cells, not associated with the vasculature, as a possible independent
marker of unfavorable prognosis in women with breast-infiltrative ductal carcinoma (I and II
stages). Our study suggests that this novel result can be useful prognostic biomarker that would
not only allow for more accurate selection of patients who would benefit from systemic therapy
but could also lead to the development of new therapeutic strategies. We think that this finding
can be considered a trigger for larger studies in this setting.
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